Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Anebulo Pharmaceuticals, Inc. (ANEB : NSDQ)

• Company Description    Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $3.18 Daily Weekly Monthly 20 Day Moving Average: 4,477 shares Shares Outstanding: 23.34 (millions) Market Capitalization: $74.24 (millions) Beta: 52 Week High: $9.33 52 Week Low: $2.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.05% -19.02% 12 Week -54.57% -48.94% Year To Date -48.29% -36.83%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1415 RANCH ROAD 629 SOUTH SUITE 201 - LAKEWAY,TX 78734 USA ph: 737-203-5270 fax: - ir@anebulo.com http://www.anebulo.com

• General Corporate Information    Officers Daniel Schneeberger - Chief Executive Officer Joseph F. Lawler - Chairman Rex Merchant - Chief Financial Officer Aron R. English - Director Jason Aryeh - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 034569103 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/28/22 Share - Related Items Shares Outstanding: 23.34 Most Recent Split Date: (:1) Beta: Market Capitalization: $74.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/28/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.33 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 88.41% vs. Previous Quarter: -60.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -36.12 12/31/21 - -28.23 09/30/21 - -35.76 ROA 03/31/22 - -35.66 12/31/21 - -27.82 09/30/21 - -35.04 Current Ratio 03/31/22 - 201.08 12/31/21 - 379.70 09/30/21 - 33.72 Quick Ratio 03/31/22 - 201.08 12/31/21 - 379.71 09/30/21 - 33.72 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.74 12/31/21 - 0.81 09/30/21 - 0.85 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©